Allergan Bolsters Blockbuster Botox With Topical Toxin Buy
This article was originally published in Scrip
Executive Summary
Allergan PLC will pay $90m up front to acquire the topical botulinum toxin maker Anterios Inc. in a move that may protect and improve the company's position in aesthetic and therapeutic indications in which the blockbuster wrinkle-reducer and migraine-reliever Botox (onabotulinumtoxinA) is approved.
You may also be interested in...
Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain
Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.
Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.